Here, we report a case that demonstrates a durable response to amivantamab monotherapy in a patient with uncommon EGFR mutations (G719A, A289V) in NSCLC, who developed leptomeningeal disease (LMD) while on osimertinib. Here, EGFR is linked to Langer mesomelic dysplasia.